MiNK Therapeutics, Inc. (INKT)

Biological Products, (No Diagnostic Substances) · market cap $63M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-13 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

MiNK Therapeutics (INKT) is a micro-cap biological products company with 23 employees and a $53M market cap, developing agenT-797, an iNKT cell therapy currently in Phase 2 for pneumonia. The company carries $9.5M in cash (~16.5 months runway) and has generated no meaningful revenue since 2022, with cumulative losses exceeding $100M over the tracked period.

The catalyst path

2026-11-13 (est.)Earningsimp 5/10
2027-06-15 (est.)Phase 2 · agenT-797imp 7/10

Pipeline

Asset	Phase	Indication
agenT-797	Phase 2	Pneumonia

Price & technical context

3-month

+15.3%

6-month

+7.1%

12-month

-20.8%

52-wk range

$8.56–$15.19

vs 50-day MA

+6.0%

vs 200-day MA

+7.3%

Realized vol

70.6%

Max drawdown

-86.7%

Daily closes through 2026-10-05. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for INKT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.